Concurrent nivolumab and metformin in diabetic cancer patients: is it safe and more active?
Background/Aim: Recent evidence suggests potential synergistic antitumor effects of the
combination of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune …
combination of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune …
[PDF][PDF] Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy
M Bastin, H Mosbah, A Carlier, A Boudifa… - Diabetes & …, 2020 - Elsevier
Programmed cell death-1 (PD-1) inhibitors have demonstrated encouraging results in
malignancies refractory to standard chemotherapy regimens. These immune checkpoint …
malignancies refractory to standard chemotherapy regimens. These immune checkpoint …
Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC
N Matsuura, G Koh, C Konishi, S Minamino… - Cancer Immunology …, 2018 - Springer
Abstract Programmed cell death-1 (PD-1) and programmed cell death-ligand-1 (PD-L1)
inhibitors have been highlighted in the field of cancer treatment. The interaction between PD …
inhibitors have been highlighted in the field of cancer treatment. The interaction between PD …
[HTML][HTML] Fulminant diabetes in a patient with advanced melanoma on nivolumab
N Chokr, H Farooq, E Guadalupe - Case Reports in Oncological …, 2018 - hindawi.com
Background. Anti-PD-1 agents were approved for advanced melanoma after the landmark
trial Checkmate-037. Anti-PD-1 agents can breach immunologic tolerance. Fulminant …
trial Checkmate-037. Anti-PD-1 agents can breach immunologic tolerance. Fulminant …
[HTML][HTML] Development of type 1 diabetes after cancer immunotherapy
JB Hao, A Renno, S Imam, M Alfonso-Jaume… - AACE Clinical Case …, 2017 - Elsevier
Objective: Nivolumab, anti–programmed cell death 1 monoclonal antibody, is a newly Food
and Drug Administration–approved biologic for the treatment of metastatic melanoma. New …
and Drug Administration–approved biologic for the treatment of metastatic melanoma. New …
Nivolumab‐induced autoimmune diabetes
JTK Chan, E Jones - Journal of Pharmacy Practice and …, 2017 - Wiley Online Library
Background Advances in research on lung cancer treatment have extended to manipulating
the immune system for cancer treatment. A new class of monoclonal antibodies, which …
the immune system for cancer treatment. A new class of monoclonal antibodies, which …
Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event
M Yilmaz - Journal of Oncology Pharmacy Practice, 2020 - journals.sagepub.com
Background Immune checkpoint inhibitors are medications that activate anti-tumor
responses by disrupting the inhibitory signaling to T cells. Nivolumab is an immune …
responses by disrupting the inhibitory signaling to T cells. Nivolumab is an immune …
[HTML][HTML] New-onset insulin-dependent diabetes due to nivolumab
Nivolumab, a monoclonal antibody against programmed cell death-1 receptor, is
increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is …
increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is …
[HTML][HTML] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
MZ Afzal, RR Mercado, K Shirai - Journal for immunotherapy of cancer, 2018 - Springer
Background Metformin is one of the biguanides commonly used in patients with type II
Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits the cell …
Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits the cell …
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
J Martin-Liberal, AJS Furness, K Joshi… - Cancer Immunology …, 2015 - Springer
The anti programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab have
been recently licensed by the Food and Drug Administration for the treatment of advanced …
been recently licensed by the Food and Drug Administration for the treatment of advanced …